Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of CDVAX in Healthy Adults
NCT02991417Phase 1Terminated
- Start
- Jan 2017
- Primary completion
- Mar 2017
- Modality
- Microbiome Therapeutics, Vaccines & Immunotherapeutics
01
Overview
Phase 1, open-label, single-arm trial of CDVAX in Clostridioides difficile infection (CDI). Primary endpoint: Incidence and severity of adverse events at 70 days. Started Jan 2017; status: terminated.
02
Drugs
CDVAX
03
Conditions
Clostridioides difficile infection (CDI)
Beyond the preview
Go deeper on NCT02991417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02991417.